Abstract: Objective:To evaluate the clinical efficacy of infusion of high-dose interleukin ( IL )- 2-activated allogeneic haploi-dentical peripheral blood stem cells ( haplo-PBSCs ) among patients with advanced intractable renal cell carcinoma ( RCC ). Methods: Ten advanced RCC patients and haploidentical relatives were enrolled as donors for haplo-PBSCs in this treatment. All patients accept-ed one cycle of activated haplo-PBSCs. The clinical and immunologic responses were evaluated. Results: A range from 2.3 to 5.5 ×10¹⁰of activated haplo-PBSCs were harvested after exposure to rhIL- 2, along with a significant increase in the proportion of natural killer ( NK ) cells and activated lymphocytes ( CD 69+ and CD 25+ ), and enhanced cytotoxicity of haplo-PBSCs for renal cell carcino -ma. After treatment,2 ( 2/10) cases of partial remission ( PR ), 6 ( 6/10) cases of stable disease ( SD ), and 2 ( 2/10) cases of progres-sive disease ( PD )were identified among the 10patients. The median progression-free survival ( PFS ) of all 10patients was5.5 months ( 3-14months ). Conclusion:The adoptive transfusion of IL- 2-activated haplo-PBSCs can induce sustained anti-tumor effects for advanced intractable RCC patients who do not respond to conventional immunotherapy.